To analyze the immune response in more detail, we performed a dedicated study with AAV8.RS-mIL-12-noCpG in the orthotopic HCC model with the same schedule as before and euthanized animals for specimen collection at three different time-points: on day 7 (after first tet administration), day 8, and day 14 (three days after the last tet dose). The gene discussed is SPRR2A; the disease is hepatocellular carcinoma.